Dr. Timothy Yap, MD

• Medical Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer, 2020-12-16

• The Principles and Practice of PARP Inhibitor Therapy, 2021-10-29

• Evaluation of Deviation From Planned Cohort Size and Operating Characteristics of Phase 1 Trials Deviation From Cohort Size and Operating Characteristics of Phase 1 Trials, 2021-02-17

• The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response, 2020-12-16

• AHUWE1defect causes PARP inhibitor resistance by modulating the BRCA1-?11q splice variant, 2023-07-25

• Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study, 2021-09-25

• A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation, 2023-06-14

• Actionability classification of variants of unknown significance correlates with functional effect, 2023-07-15

• Development of Immunotherapy Combination Strategies in Cancer, 2021-04-02

• First in Human Phase 1/2 ICONIC Trial of the ICOS agonist vopratelimab alone and with nivolumab: ICOS-hi CD4 T cell populations and predictors of response, 2022-09-01

• Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences, 2022-05-24

• SHP2 inhibition sensitizes diverse oncogene-addicted solid tumors to re-treatment with targeted therapy, 2023-08-04

• Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial, 2022-08-23

• Sequential therapy with PARP and WEE1 inhibitors minimizes toxicity while maintaining efficacy, 2019-06-10

• Targeting the Replication Stress Response through Synthetic Lethal Strategies in Cancer Medicine, 2021-06-30

• Development of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor and Immunotherapy Combinations: Progress, Pitfalls and Promises, 2021-06-19

• Antibody-drug conjugates in lung cancer: dawn of a new era?, 2023-01-11

• Application of Real-World Data to External Control Groups in Oncology Clinical Trial Drug Development, 2022-01-06

• Shotgun: A Bayesian seamless phase I-II design to accelerate the development of targeted therapies and immunotherapy, 2021-03-10

• National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH), 2023-04-14

• PRECISION ONCOLOGY DECISION SUPPORT: CURRENT APPROACHES AND STRATEGIES FOR THE FUTURE, 2018-02-02

• PARP inhibitors: enhancing efficacy through rational combinations, 2023-07-10

• Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib study, 2021-11-03

• Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours, 2021-05-26

• Targeting the DDR beyond PARP inhibitors: Novel agents and rational combinations, 2022-07-05

• Phase II Study of Pembrolizumab Efficacy and Safety in Women with Recurrent Small Cell Neuroendocrine Carcinoma of the Lower Genital Tract, 2020-06-11

• BRD4 inhibition is synthetic lethal with PARP inhibitors through the induction of homologous recombination deficiency, 2018-03-12

• Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors, 2021-12-29

• First-in-Human Trial of the Oral Ataxia Telangiectasia and Rad3-Related Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors, 2020-09-28

• Development of the PARP inhibitor talazoparib for the treatment of advancedBRCA1andBRCA2mutated breast cancer, 2021-07-26

• Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition, 2021-12-01

• TargetingBRAFMutant Colorectal Cancer: Progress in Combination Strategies, 2017-02-07

• Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies, 2023-04-18

• Precision combination therapies based on recurrent oncogenic co-alterations, 2022-06-02

• Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results, 2023-06-05

• Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology, 2022-10-27

• ClinicalBRCA1/2reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance, 2020-07-22

• Targeted Inhibition of DNA-PKcs, ATM, ATR, PARP, and Rad51 Modulate Response to X Rays and Protons, 2022-10-01

• ATR inhibition induces CDK1-SPOP signaling and enhances anti-PD-L1 cytotoxicity in prostate cancer, 2021-06-24

• A Population of Heterogeneous Breast Cancer Patient Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild Type Tumors, 2017-11-01

• PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma, 2021-07-30

• Oxidative Phosphorylation is a Metabolic Vulnerability in Chemotherapy Resistant Triple Negative Breast Cancer, 2021-09-13

• PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness, 2018-11-27

• State-of-the-art strategies for targeting the DNA damage response in cancer, 2021-07-26

• Metabolic biomarkers of response to the AKT inhibitor MK-2206 in pre-clinical models of human colorectal and prostate carcinoma, 2018-10-31

• A Phase I Dose Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies, 2021-03-26